BACKGROUND:Functional dyspepsia (FD) is a common problem affecting up to 10-25% of individuals. FD accounts for significant health care costs and affects quality of life but has no definitive treatment. OBJECTIVES: The Functional Dyspepsia Treatment Trial (FDTT) aims to test whether treatment with an antidepressant (amitriptyline or escitalopram) leads to improvement of symptoms in patients with moderate to severe FD. DESIGN: The FDTT is an international multicenter, parallel group, randomized, double-blind, placebo-controlled trial to evaluate whether 12 weeks of treatment with escitalopram or amitriptyline improves FD symptoms compared to treatment with placebo. Secondly, it is hypothesized that acceleration of solid gastric emptying, reduction of postprandial satiation, and enhanced gastric volume change with a meal will be significant positive predictors of short- and long-term outcomes for those on antidepressants vs. placebo. The third aim is to examine whether polymorphisms of GNβ3 and serotonin reuptake transporter influence treatment outcomes in FD patients receiving a tricyclic antidepressant, selective serotonin reuptake inhibitor therapy, orplacebo. METHODS: The FDTT enrollment began in 2006 and is scheduled to randomize 400 patients by the end of 2012 to receive an antidepressant or placebo for 12 weeks, with a 6-month post-treatment follow-up. The study incorporates multiple validated questionnaires, physiological testing, and specific genetic evaluations. The protocol was approved by participating centers' Institutional Review Boards and an independent Data Safety Monitoring Board was established for monitoring to ensure patient safety and a single interim review of the data in December 2010 (ClinicalTrials.gov number NCT00248651).
RCT Entities:
BACKGROUND:Functional dyspepsia (FD) is a common problem affecting up to 10-25% of individuals. FD accounts for significant health care costs and affects quality of life but has no definitive treatment. OBJECTIVES: The Functional Dyspepsia Treatment Trial (FDTT) aims to test whether treatment with an antidepressant (amitriptyline or escitalopram) leads to improvement of symptoms in patients with moderate to severe FD. DESIGN: The FDTT is an international multicenter, parallel group, randomized, double-blind, placebo-controlled trial to evaluate whether 12 weeks of treatment with escitalopram or amitriptyline improves FD symptoms compared to treatment with placebo. Secondly, it is hypothesized that acceleration of solid gastric emptying, reduction of postprandial satiation, and enhanced gastric volume change with a meal will be significant positive predictors of short- and long-term outcomes for those on antidepressants vs. placebo. The third aim is to examine whether polymorphisms of GNβ3 and serotonin reuptake transporter influence treatment outcomes in FDpatients receiving a tricyclic antidepressant, selective serotonin reuptake inhibitor therapy, or placebo. METHODS: The FDTT enrollment began in 2006 and is scheduled to randomize 400 patients by the end of 2012 to receive an antidepressant or placebo for 12 weeks, with a 6-month post-treatment follow-up. The study incorporates multiple validated questionnaires, physiological testing, and specific genetic evaluations. The protocol was approved by participating centers' Institutional Review Boards and an independent Data Safety Monitoring Board was established for monitoring to ensure patient safety and a single interim review of the data in December 2010 (ClinicalTrials.gov number NCT00248651).
Authors: A L Blum; N J Talley; C O'Moráin; S V van Zanten; J Labenz; M Stolte; J A Louw; A Stubberöd; A Theodórs; M Sundin; E Bolling-Sternevald; O Junghard Journal: N Engl J Med Date: 1998-12-24 Impact factor: 91.245
Authors: S J Veldhuyzen van Zanten; C Cleary; N J Talley; T C Peterson; O Nyrén; L A Bradley; M Verlinden; G N Tytgat Journal: Am J Gastroenterol Date: 1996-04 Impact factor: 10.864
Authors: N J Talley; V Meineche-Schmidt; P Paré; M Duckworth; P Räisänen; A Pap; H Kordecki; V Schmid Journal: Aliment Pharmacol Ther Date: 1998-11 Impact factor: 8.171
Authors: B E Lacy; N J Talley; G R Locke; E P Bouras; J K DiBaise; H B El-Serag; B P Abraham; C W Howden; P Moayyedi; C Prather Journal: Aliment Pharmacol Ther Date: 2012-05-16 Impact factor: 8.171
Authors: Nicholas J Talley; G Richard Locke; Yuri A Saito; Ann E Almazar; Ernest P Bouras; Colin W Howden; Brian E Lacy; John K DiBaise; Charlene M Prather; Bincy P Abraham; Hashem B El-Serag; Paul Moayyedi; Linda M Herrick; Lawrence A Szarka; Michael Camilleri; Frank A Hamilton; Cathy D Schleck; Katherine E Tilkes; Alan R Zinsmeister Journal: Gastroenterology Date: 2015-04-25 Impact factor: 22.682
Authors: B E Lacy; Y A Saito; M Camilleri; E Bouras; J K DiBaise; L M Herrick; L A Szarka; K Tilkes; A R Zinsmeister; N J Talley Journal: Am J Gastroenterol Date: 2017-12-19 Impact factor: 10.864
Authors: Yuri A Saito; G Richard Locke; Ann E Almazar; Ernest P Bouras; Colin W Howden; Brian E Lacy; John K DiBaise; Charlene M Prather; Bincy P Abraham; Hashem B El-Serag; Paul Moayyedi; Linda M Herrick; Lawrence A Szarka; Michael Camilleri; Frank A Hamilton; Cathy D Schleck; Katherine E Tilkes; Alan R Zinsmeister; Nicholas J Talley Journal: Am J Gastroenterol Date: 2017-03-14 Impact factor: 10.864
Authors: Linda M Herrick; Giles Richard Locke; Cathy D Schleck; Alan R Zinsmeister; Vickie Treder; Nicholas J Talley Journal: Scand J Gastroenterol Date: 2015-03-11 Impact factor: 2.423
Authors: Jeffrey M Lackner; Laurie Keefer; James Jaccard; Rebecca Firth; Darren Brenner; Jason Bratten; Laura J Dunlap; Changxing Ma; Mark Byroads Journal: Contemp Clin Trials Date: 2012-07-28 Impact factor: 2.226